跳到正文
原文
Medical Xpress·· 2026-10-16AI 评分53

炎性乳腺癌进展快且常无肿块,皮肤改变是警示信号

Inflammatory breast cancer: Fast-moving form often lacks lump as warning sign

AI 导读

Mayo Clinic 外科肿瘤学家 Tina Hieken 指出,炎性乳腺癌通常不形成肿块,而是单侧乳房皮肤在数月内迅速改变,出现发红、发热和橘皮样外观,因而易被误诊为蜂窝织炎、乳腺炎或佩吉特病。

正文
breast cancer
Credit: Anna Tarazevich from Pexels

Inflammatory breast cancer is a fast-moving cancer that doesn't usually form a lump; instead, the skin on one breast changes rapidly, explains Tina Hieken, M.D., a surgical oncologist at Mayo Clinic Comprehensive Cancer Center.

Inflammatory breast cancer often comes with symptoms that mimic inflammation of the breast, such as a change in skin color to a pink, red, purple or bruised appearance, unusual warmth in the affected breast and orange peel–like skin, a symptom known as peau d'orange.

As a result, inflammatory breast cancers may be misdiagnosed as cellulitis, mastitis, Paget's disease of the breast or other more benign conditions.

Inflammatory breast cancer accounts for roughly 1% to 5% of breast cancer diagnoses and 10% of breast cancer deaths, statistics show.

"When there are changes in the skin of the breast, particularly in women who aren't nursing and do not have breastfeeding-associated redness, that can be a warning sign of cancer and should be evaluated by a medical professional," Hieken says.

"In inflammatory breast cancer, symptoms can develop within a few months," she notes. "That's different from someone noting a lump in the breast over a period of time, and then secondarily, skin changes in the breast over a year or longer."

In inflammatory breast cancer, abnormal cells go through the lymphatic channels in skin and soft tissue, accounting for the skin changes in the breast, Hieken explains.

Inflammatory breast cancer treatment

Inflammatory breast cancer is treated first with systemic therapy: a treatment that goes through the whole body, she says. That therapy is based on the cancer's biological features, or subtype, such as whether it expresses the estrogen receptor or overexpresses the HER2 protein.

The systemic therapy is usually delivered intravenously and could be:

  • Chemotherapy directed at rapidly dividing cells.
  • Targeted therapy aimed at cells that overexpress the HER2 protein.
  • Immunotherapy to help the body fight cancer that doesn't express the estrogen receptor or the HER2 protein; this is the least common type, Hieken says.

Then, surgery includes removal of the breast and nearby lymph nodes, typically followed by radiation that includes the chest, armpit and shoulder. This three-mode approach of whole-body therapy, surgery and radiation is critical to disease control for cancer that has a high risk of spreading to other parts of the body or recurring in the breast and surrounding area, Hieken says. More common forms of breast cancer may not require all types of available treatments.

Advances in inflammatory breast cancer care

There have been several innovations in the treatment of inflammatory breast cancer.

"Very similar to noninflammatory breast cancer, giving treatment at the beginning that is designed for one of those three or four subtypes of breast cancer is probably the biggest innovation," Hieken says.

"I think in parallel, the other big innovation is better cross-sectional imaging so that, at the outset, we know whether patients have disease that has spread beyond the breast and the regional lymph nodes."

Among the breast cancer subtypes, progress has particularly been made in HER2-positive inflammatory breast cancer, with the addition of two different drugs that work in a complementary way to block the effects of the HER2 protein overexpression, she adds.

"It's been a huge advantage and has really improved outcomes for women," Hieken says. "Then, for those women who have less than a complete response to that systemic treatment, there are new targeted therapies that can be given after surgery."

Another improvement is intensity-modulated radiotherapy, or IMRT, that is delivered using CT-integrated planning, she says. This allows the care team to look at a patient in three dimensions and determine how to personalize radiation therapy to minimize the effects through such techniques as having the patient practice breath-holding or lie on her stomach during radiation therapy.

"We're learning a lot," Hieken adds.

Who's behind this story?

Sadie Harley

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Alexander Pol

Alexander Pol

PhD nano-engineering from Delft University. Published researcher and journal reviewer. Brings scientific insight to content standards. Full profile →

Citation: Inflammatory breast cancer: Fast-moving form often lacks lump as warning sign (2026, October 16) retrieved 16 October 2026 from https://medicalxpress.com/news/2026-10-inflammatory-breast-cancer-fast-lacks.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com